Cover Image
Market Research Report

Middle East and Africa Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026

Published by Data Bridge Market Research Private Limited Product code 836039
Published Content info 350 Pages
Delivery time: 1-2 business days
Price
Back to Top
Middle East and Africa Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026
Published: April 1, 2019 Content info: 350 Pages
Description

Middle East and Africa lung cancer therapeutics market is expected to grow at a healthy CAGR of 9.9% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:

By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (South Africa , Rest of Middle East & Africa) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

  • On the basis of cancer type, the non-small cell lung cancer is dominating the global lung cancer therapeutics market. Lung cancer is the second most common cancer type including small cell and non-small cell lung cancer. Amongst these 80-85% cases are non-small cell lung cancer. This type of cancer grows and spreads more slowly than small cell lung cancer and therefore it is dominating the market.
  • On the basis of molecule type, the small molecule segment is dominating the global lung cancer therapeutics market. The small molecule better effects and progression free survival of lung cancer and these agents also inhibit the growth of the metastatic cell. Due to all these reasons they are more preferred than the other types.
  • On the drug class, the alkylating drug segment is dominating the lung cancer therapeutics market. This is the first discovered drug for the treatment of cancer. Alkylating directly damage DNA and prevents the cancer cells cell division. The alkylating agent can be used in every stage of cancer. This drug shows pre and post stage. This drug also shows reduced drug accumulation and the increased detoxification.
  • On the basis of treatment type, the chemotherapy segment is dominating the lung cancer therapeutics market. Chemotherapy is a traditional process in which drugs are used to kill or inhibit cancerous cells as it is the most accepted treatment. Whereas, targeted therapy is becoming more familiar in the lung cancer sector as these classes of drugs specifically focuses on specific genetic mutations present in the tumor cells.
  • On the basis of therapy type, single drug therapy segment is dominating the lung cancer therapeutics market. The single drug therapy is the first evolved therapy used for the treatment of lung cancer. Single drug therapy is dominating the market as it is mostly preferred for the treatment of old age population, patients with poor performance status and patients who are not able to take the combination therapy. Whereas the combination drug therapy is expected to grow in future as many combination drugs are under clinical trials and is expected to launch soon. Also, few studies have shown that combination drugs can have better results as compared to the single drug therapy which will contribute to the growth of the combination therapy in the forecast period.
  • On the basis of end user, hospitals segment is dominating the lung cancer therapeutics market. The hospital segment is dominating in the lung cancer therapeutics because hospitals provides many advantages over the other segments which includes, 24hours supportive care, immediate care for the emergency, availability of physicians, surgeons and medication.
  • On the basis of distribution channel, hospital pharmacy segment is dominating the lung cancer therapeutics market. Hospital pharmacy is dominating the global lung cancer therapeutics market as the lung cancer therapy products are prescribed based which is majorly available in hospital pharmacy.

Key Market Players:

The key market players for Middle East and Africa lung cancer therapeutics market are listed below:

  • Takeda Pharmaceutical Company Limited
  • ONO PHARMACEUTICAL CO., LTD.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Eli Lilly and Company.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • CELGENE CORPORATION
  • AMGEN INC.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • ALLERGAN
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Astellas Pharma Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Others
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 RESEARCH METHODOLOGY
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR MARKET CHALLENGE MATRIX
  • 2.9 DBMR VENDOR SHARE ANALYSIS
  • 2.10 MULTIVARIATE MODELLING
  • 2.11 PRODUCT TIME LINE
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING CASES OF LUNG CANCER
    • 3.1.2 GROWING NUMBER OF SMOKERS
    • 3.1.3 GOVERNMENT/ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS
    • 3.1.4 INCREASING AWARENESS
    • 3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES
  • 3.2 RESTRAINS
    • 3.2.1 PRICING PRESSURE
    • 3.2.2 HIGH COST
  • 3.3 OPPORTUNITIES
    • 3.3.1 APPROVALS AND PRODUCT PIPEPLINE
    • 3.3.2 HEALTH TOURISM
    • 3.3.3 NEW PRODUCT LAUNCHES

  • 3.4 CHALLENGES
    • 3.4.1 SIDE EFFECTS
    • 3.4.2 LACK OF NUMBER OF ONCOLOGISTS
    • 3.4.3 UNMET MEDICAL NEEDS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY OF LUNG CANCER

7 REGULATORY PROCEDURE

8 PIPELINE DRUGS

9 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-SMALL CELL LUNG CANCER
    • 9.2.1 SQUAMOUS CELL CARCINOMA
    • 9.2.2 PULMONARY ADENOCARCINOMA
    • 9.2.3 ADENOSQUAMOUS CARCINOMA (ASC)
    • 9.2.4 LARGE CELL CARCINOMA
    • 9.2.5 SARCOMATOID CARCINOMA
    • 9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER
    • 9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA
      • 9.2.7.1 ADENOID CYSTIC CARCINOMA
      • 9.2.7.2 MUCOEPIDERMOID CARCINOMA
      • 9.2.7.3 ACINIC CELL CARCINOMA
      • 9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA
      • 9.2.7.5 GRANULAR CELL LUNG TUMORS
  • 9.3 METASTATIC LUNG CANCER
  • 9.4 MESOTHELIOMA
  • 9.5 CHEST WALL TUMORS
    • 9.5.1 PRIMARY TUMORS
    • 9.5.2 METASTATIC TUMORS
    • 9.5.3 SARCOMAS
  • 9.6 PULMONARY NEUROENDOCRINE TUMORS
    • 9.6.1 CARCINOID TUMORS
      • 9.6.1.1 TYPICAL CARCINOID TUMORS
      • 9.6.1.2 ATYPICAL CARCINOID TUMORS
    • 9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA
    • 9.6.3 SMALL-CELL LUNG CANCER
      • 9.6.3.1 SMALL CELL CARCINOMA
      • 9.6.3.2 COMBINED SMALL CELL CARCINOMA
  • 9.7 MEDIASTINAL TUMORS
    • 9.7.1 GERM CELL TUMORS
    • 9.7.2 LYMPHOMAS
    • 9.7.3 THYMOMAS

10 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE

  • 10.1 OVERVIEW
  • 10.2 SMALL MOLECULE
  • 10.3 BILOGICS

11 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS

  • 11.1 OVERVIEW
  • 11.2 ALKYLATING AGENTS
  • 11.3 ANTIMETABOLITES
  • 11.4 MITOTIC INHIBITORS
  • 11.5 MULTIKINASE INHIBITORS
  • 11.6 EGFR INHIBITORS
  • 11.7 OTHERS

12 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE

  • 12.1 OVERVIEW
  • 12.2 RADIATION THERAPY
    • 12.2.1 EXTERNAL BEAM
    • 12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY)
    • 12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)
    • 12.2.4 STEREOTACTIC RADIOSURGERY (SRS)
  • 12.3 CHEMOTHERAPY
    • 12.3.1 CISPLATIN
    • 12.3.2 PACLITAXEL (TAXOL)
    • 12.3.3 VINORELBINE (NAVELBINE)
    • 12.3.4 DOCETAXEL (TAXOTERE)
    • 12.3.5 ALIMTA
    • 12.3.6 GEMCITABINE (GEMZAR)
    • 12.3.7 DURVALUMAB (IMFINZI)
    • 12.3.8 OTHERS
  • 12.4 TARGETED THERAPY
    • 12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS
    • 12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
    • 12.4.3 ANTI-ANGIOGENESIS THERAPY
    • 12.4.4 MONOCLONAL ANTIBODIES
    • 12.4.5 OTHERS
  • 12.5 IMMUNOTHERAPY
    • 12.5.1 ATEZOLIZUMAB (TECENTRIQ)
    • 12.5.2 DURVALUMAB (IMFINZI)
    • 12.5.3 NIVOLUMAB (OPDIVO)
    • 12.5.4 PEMBROLIZUMAB (KEYTRUDA)
  • 12.6 OTHERS

13 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE

  • 13.1 OVERVIEW
  • 13.2 SINGLE DRUG THERAPY
  • 13.3 COMBINATION THERAPY

14 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 SPECIALTY CLINICS
  • 14.4 HOMECARE
  • 14.5 OTHERS

15 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE
  • 15.5 OTHERS

16 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

  • 16.1 MIDDLE EAST AND AFRICA
    • 16.1.1 SOUTH AFRICA
    • 16.1.2 REST OF MIDDLE EAST AND AFRICA
    • 16.1.3 EGYPT
    • 16.1.4 SAUDI ARABIA
    • 16.1.5 UNITED ARAB EMIRATES
    • 16.1.6 ISRAEL

17 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 COMPANY PROFILES

  • 18.1 F. HOFFMANN-LA ROCHE LTD
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 GEOGRAPHICAL PRESENCE
    • 18.1.4 COMPANY SHARE ANALYSIS
    • 18.1.5 PRODUCT PORTFOLIO
    • 18.1.6 RECENT DEVELOPMENTS
  • 18.2 MERCK & CO., INC.
    • 18.2.1 COMPANY OVERVIEW
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 GEOGRAPHICAL PRESENCE
    • 18.2.4 COMPANY SHARE ANALYSIS
    • 18.2.5 PRODUCT PORTFOLIO
    • 18.2.6 RECENT DEVELOPMENTS
  • 18.3 BRISTOL-MYERS SQUIBB COMPANY
    • 18.3.1 COMPANY OVERVIEW
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 GEOGRAPHICAL PRESENCE
    • 18.3.4 COMPANY SHARE ANALYSIS
    • 18.3.5 PRODUCT PORTFOLIO
    • 18.3.6 RECENT DEVELOPMENTS

  • 18.4 ASTRAZENECA
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 GEOGRAPHICAL PRESENCE
    • 18.4.4 COMPANY SHARE ANALYSIS
    • 18.4.5 PRODUCT PORTFOLIO
    • 18.4.6 RECENT DEVELOPMENTS
  • 18.5 ELI LILLY AND COMPANY
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 GEOGRAPHICAL PRESENCE
    • 18.5.4 COMPANY SHARE ANALYSIS
    • 18.5.5 PRODUCT PORTFOLIO
    • 18.5.6 RECENT DEVELOPMENTS
  • 18.6 ALLERGAN
    • 18.6.1 COMPANY OVERVIEW
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 GEOGRAPHICAL PRESENCE
    • 18.6.4 PRODUCT PORTFOLIO
    • 18.6.5 RECENT DEVELOPMENTS
  • 18.7 AMGEN INC.
    • 18.7.1 COMPANY OVERVIEW
    • 18.7.2 REVENUE ANALYSIS
    • 18.7.3 GEOGRAPHICAL PRESENCE
    • 18.7.4 PRODUCT PORTFOLIO
    • 18.7.5 RECENT DEVELOPMENTS
  • 18.8 ASTELLAS PHARMA INC.
    • 18.8.1 COMPANY OVERVIEW
    • 18.8.2 REVENUE ANALYSIS
    • 18.8.3 GEOGRAPHICAL PRESENCE
    • 18.8.4 PRODUCT PORTFOLIO
    • 18.8.5 RECENT DEVELOPMENTS
  • 18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 18.9.1 COMPANY OVERVIEW
    • 18.9.2 REVENUE ANALYSIS
    • 18.9.3 GEOGRAPHICAL PRESENCE
    • 18.9.4 PRODUCT PORTFOLIO
    • 18.9.5 RECENT DEVELOPMENTS

  • 18.10 CELGENE CORPORATION
    • 18.10.1 COMPANY OVERVIEW
    • 18.10.2 REVENUE ANALYSIS
    • 18.10.3 GEOGRAPHICAL PRESENCE
    • 18.10.4 PRODUCT PORTFOLIO
    • 18.10.5 RECENT DEVELOPMENTS
  • 18.11 DR. REDDY'S LABORATORIES LTD.
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 REVENUE ANALYSIS
    • 18.11.3 GEOGRAPHICAL PRESENCE
    • 18.11.4 PRODUCT PORTFOLIO
    • 18.11.5 RECENT DEVELOPMENTS
  • 18.12 GLAXOSMITHKLINE PLC.
    • 18.12.1 COMPANY OVERVIEW
    • 18.12.2 REVENUE ANALYSIS
    • 18.12.3 GEOGRAPHICAL PRESENCE
    • 18.12.4 PRODUCT PORTFOLIO
    • 18.12.5 RECENT DEVELOPMENTS
  • 18.13 JOHNSON & JOHNSON SERVICES, INC.
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 REVENUE ANALYSIS
    • 18.13.3 GEOGRAPHICAL PRESENCE
    • 18.13.4 PRODUCT PORTFOLIO
    • 18.13.5 RECENT DEVELOPMENTS
  • 18.14 NOVARTIS AG
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 REVENUE ANALYSIS
    • 18.14.3 GEOGRAPHICAL PRESENCE
    • 18.14.4 PRODUCT PORTFOLIO
    • 18.14.5 RECENT DEVELOPMENT
  • 18.15 ONO PHARMACEUTICAL CO., LTD.
    • 18.15.1 COMPANY OVERVIEW
    • 18.15.2 REVENUE ANALYSIS
    • 18.15.3 GEOGRAPHICAL PRESENCE
    • 18.15.4 PRODUCT PORTFOLIO
    • 18.15.5 RECENT DEVELOPMENTS

  • 18.16 PFIZER INC.
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 RECENT FINANCIALS
    • 18.16.3 GEOGRAPHICAL PRESENCE
    • 18.16.4 PRODUCT PORTFOLIO
    • 18.16.5 RECENT DEVELOPMENTS
  • 18.17 SANOFI
    • 18.17.1 COMPANY OVERVIEW
    • 18.17.2 REVENUE ANALYSIS
    • 18.17.3 GEOGRAPHICAL PRESENCE
    • 18.17.4 PRODUCT PORTFOLIO
    • 18.17.5 RECENT DEVELOPMENTS
  • 18.18 SUMITOMO DAINIPPON PHARMA CO., LTD.
    • 18.18.1 COMPANY OVERVIEW
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 GEOGRAPHICAL PRESENCE
    • 18.18.4 PRODUCT PORTFOLIO
    • 18.18.5 RECENT DEVELOPMENTS
  • 18.19 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 REVENUE ANALYSIS
    • 18.19.3 GEOGRAPHICAL PRESENCE
    • 18.19.4 PRODUCT PORTFOLIO
    • 18.19.5 RECENT DEVELOPMENTS
  • 18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 18.20.1 COMPANY OVERVIEW
    • 18.20.2 REVENUE ANALYSIS
    • 18.20.3 GEOGRAPHICAL PRESENCE
    • 18.20.4 PRODUCT PORTFOLIO
    • 18.20.5 RECENT DEVELOPMENTS
  • 18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 18.21.1 COMPANY OVERVIEW
    • 18.21.2 REVENUE ANALYSIS
    • 18.21.3 GEOGRAPHICAL PRESENCE
    • 18.21.4 PRODUCT PORTFOLIO
    • 18.21.5 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLE

LIST OF TABLES

  • TABLE 1 PREVALENCE OF SUBTYPES OF LUNG CARCINOMA IN SMOKERS AND NEVER-SMOKERS
  • TABLE 2 COST OF TARGETED THERAPIES FOR THE TREATMENT OF NSCLC (2018)
  • TABLE 3 COST OF IMMUNOTHERAPIES FOR THE TREATMENT OF NSCLC (2018)

TABLE 4 SOME OF THE PIPELINE LUNG CANCER DRUGS ARE MENTIONED IN THE BELOW TABLE:

  • TABLE 5 AVERAGE COST OF LUNG CANCER TREATMENT (2018)
  • TABLE 6 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 7 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 8 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 9 MIDDLE EAST & AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 10 MIDDLE EAST & AFRICA METASTATIC LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 11 MIDDLE EAST & AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 12 MIDDLE EAST & AFRICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 13 MIDDLE EAST & AFRICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 14 MIDDLE EAST & AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 15 MIDDLE EAST & AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 16 MIDDLE EAST & AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 17 MIDDLE EAST & AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 18 MIDDLE EAST & AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 19 MIDDLE EAST & AFRICA MESOTHELIOMA IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 20 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 21 MIDDLE EAST & AFRICA SMALL MOLECULE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 22 MIDDLE EAST & AFRICA BIOLOGICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 23 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 24 MIDDLE EAST & AFRICA ALKYLATING AGENTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 25 MIDDLE EAST & AFRICA ANTIMETABOLITES IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 26 MIDDLE EAST & AFRICA MITOTIC INHIBITORS PRODUCTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 27 MIDDLE EAST & AFRICA MULTIKINASE INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 28 MIDDLE EAST & AFRICA EGFR INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 29 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 30 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 31 MIDDLE EAST & AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 32 MIDDLE EAST & AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 33 MIDDLE EAST & AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 34 MIDDLE EAST & AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 35 MIDDLE EAST & AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 36 MIDDLE EAST & AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 37 MIDDLE EAST & AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 38 MIDDLE EAST & AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 39 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 40 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 41 MIDDLE EAST & AFRICA SINGLE DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 42 MIDDLE EAST & AFRICA COMBINATION DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 43 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 44 MIDDLE EAST & AFRICA HOSPITALS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 45 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 46 MIDDLE EAST & AFRICA HOMECARE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 47 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 48 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 49 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 50 MIDDLE EAST & AFRICA RETAIL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 51 MIDDLE EAST & AFRICA ONLINE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 52 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 53 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 54 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 55 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 56 MIDDLE EAST & AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 57 MIDDLE EAST & AFRICA CHEST WALL TUMOR IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 58 MIDDLE EAST & AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 59 MIDDLE EAST & AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 60 MIDDLE EAST & AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 61 MIDDLE EAST & AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 62 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 63 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 64 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 65 MIDDLE EAST & AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 66 MIDDLE EAST & AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 67 MIDDLE EAST & AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 68 MIDDLE EAST & AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 69 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 70 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 71 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 72 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 73 SOUTH AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 74 SOUTH AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 75 SOUTH AFRICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 76 SOUTH AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 77 SOUTH AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 78 SOUTH AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 79 SOUTH AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 80 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 81 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 82 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 83 SOUTH AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 84 SOUTH AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 85 SOUTH AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 86 SOUTH AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 87 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 88 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 89 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 90 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 2 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: DATA VALIDATION MODEL
  • FIGURE 3 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: DROC ANALYSIS
  • FIGURE 4 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: THE MARKET CHALLENGE MATRIX
  • FIGURE 9 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET
  • FIGURE 11 COUNTRY WISE LUNG CANCER RATES IN 2018
  • FIGURE 12 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 13 INCREASING CASES OF LUNG CANCER, GROWING NUMBER OF SMOKERS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026
  • FIGURE 14 NON-SMALL CELL LUNG CANCER IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET IN 2019 & 2026
  • FIGURE 15 WORLDWIDE LUNG CANCER INCIDENCE (2018)
  • FIGURE 16 WORLDWIDE PREVALENCE OF LUNG CANCER FOR LAST 5 YEARS
  • FIGURE 17 WORLDWIDE MORTALITY RATE OF LUNG CANCER (2018)
  • FIGURE 18 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE, 2018
  • FIGURE 19 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY MOLECULE TYPE, 2018
  • FIGURE 20 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY DRUG CLASS, 2018
  • FIGURE 21 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT TYPE, 2018
  • FIGURE 22 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY THERAPY TYPE, 2018
  • FIGURE 23 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY END USER, 2018
  • FIGURE 24 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2018
  • FIGURE 25 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 26 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 27 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 28 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 29 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 30 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)
Back to Top